Form 4: VivoSim Labs CSO Granted 53,500 Stock Options

VivoSim Labs' Chief Scientific Officer, Amar Akhtar Sethi, was granted 53,500 stock options with an exercise price of $2.19, vesting over four years.

Summary

• Amar Akhtar Sethi, Chief Scientific Officer of VivoSim Labs, INC. (VIVS), was granted 53,500 derivative securities in the form of options to buy common stock.
• The options have an exercise price of $2.19 per share.
• The earliest transaction date for this grant was November 25, 2025.
• The options vest over a four-year period, with 25% vesting on November 24, 2026, and the remaining balance vesting in 12 equal quarterly installments thereafter.
• The expiration date for these options is November 25, 2035.
• Following this transaction, Mr. Sethi beneficially owns 53,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating retention and alignment of interests, though it's a standard compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a Chief Scientific Officer aligns management incentives with shareholder value.
• The long vesting schedule (four years) encourages long-term commitment and performance from a key executive.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential dilution from future option exercise, but also potential for increased executive performance and long-term value creation.
• Employees: May signal stability and commitment from leadership.

Key Dates

Recommendation

The grant of stock options to a key executive is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. It does not present new information that would significantly alter the fundamental investment outlook for VivoSim Labs, hence a 'hold' recommendation is appropriate for existing investors, while new investors should consider broader company fundamentals.

Keywords

VivoSim Labs, VIVS, Stock Options, Executive Compensation, Form 4, Insider Transaction, Amar Akhtar Sethi, Chief Scientific Officer, Equity Grant